Skip Nav Destination
Ibrutinib: the home run for cure in CLL?
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab
Issue Archive
Table of Contents
BLOOD COMMENTARIES
CLINICAL TRIALS AND OBSERVATIONS
Ibrutinib: the home run for cure in CLL?
Clinical Trials & Observations
PLENARY PAPER
PLATELETS AND THROMBOPOIESIS
Human megakaryocytes possess intrinsic antiviral immunity through regulated induction of IFITM3
Robert A. Campbell,Hansjorg Schwertz,Eugenio D. Hottz,Jesse W. Rowley,Bhanu Kanth Manne,A. Valance Washington,Robert Hunter-Mellado,Neal D. Tolley,Miles Christensen,Alicia S. Eustes,Emilie Montenont,Seema Bhatlekar,Cassandra H. Ventrone,Beth D. Kirkpatrick,Kristen K. Pierce,Stephen S. Whitehead,Sean A. Diehl,Paul F. Bray,Guy A. Zimmerman,Yasuhiro Kosaka,Patricia T. Bozza,Fernando A. Bozza,Andrew S. Weyrich,Matthew T. Rondina
BLOOD SPOTLIGHT
CLINICAL TRIALS AND OBSERVATIONS
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab
Clinical Trials & Observations
John C. Byrd,Peter Hillmen,Susan O’Brien,Jacqueline C. Barrientos,Nishitha M. Reddy,Steven Coutre,Constantine S. Tam,Stephen P. Mulligan,Ulrich Jaeger,Paul M. Barr,Richard R. Furman,Thomas J. Kipps,Patrick Thornton,Carol Moreno,Marco Montillo,John M. Pagel,Jan A. Burger,Jennifer A. Woyach,Sandra Dai,Remus Vezan,Danelle F. James,Jennifer R. Brown
HEMATOPOIESIS AND STEM CELLS
LYMPHOID NEOPLASIA
Ibrutinib therapy downregulates AID enzyme and proliferative fractions in chronic lymphocytic leukemia
Pablo Elías Morande,Mariela Sivina,Angimar Uriepero,Noé Seija,Catalina Berca,Pablo Fresia,Ana Inés Landoni,Javier M. Di Noia,Jan A. Burger,Pablo Oppezzo
There is a Blood Commentary on this article in this issue.
MYELOID NEOPLASIA
PHAGOCYTES, GRANULOCYTES, AND MYELOPOIESIS
THROMBOSIS AND HEMOSTASIS
Mouse venous thrombosis upon silencing of anticoagulants depends on tissue factor and platelets, not FXII or neutrophils
Marco Heestermans,Salam Salloum-Asfar,Tom Streef,El Houari Laghmani,Daniela Salvatori,Brenda M. Luken,Sacha S. Zeerleder,Henri M. H. Spronk,Suzanne J. Korporaal,Daniel Kirchhofer,Gerry T. M. Wagenaar,Henri H. Versteeg,Pieter H. Reitsma,Thomas Renné,Bart J. M. van Vlijmen
LETTERS TO BLOOD
Access to emergency departments for acute events and identification of sickle cell disease in refugees
Lucia De Franceschi,Caterina Lux,Frédéric B. Piel,Barbara Gianesin,Federico Bonetti,Maddalena Casale,Giovanna Graziadei,Roberto Lisi,Valeria Pinto,Maria Caterina Putti,Paolo Rigano,Rossellina Rosso,Giovanna Russo,Vincenzo Spadola,Claudio Pulvirenti,Monica Rizzi,Filippo Mazzi,Giovanbattista Ruffo,Gian Luca Forni
Anti-human CD117 antibody-mediated bone marrow niche clearance in nonhuman primates and humanized NSG mice
Hye-Sook Kwon,Aaron C. Logan,Akanksha Chhabra,Wendy W. Pang,Agnieszka Czechowicz,Keri Tate,Alan Le,Jessica Poyser,Roger Hollis,Benjamin V. Kelly,Donald B. Kohn,Irving L. Weissman,Susan S. Prohaska,Judith A. Shizuru
BLOOD WORK
-
Cover Image
Cover Image
Induction of interferon-induced transmembrane protein 3 (IFITM3) in human megakaryocytes prevents dengue virus infection. Mature CD34+-derived megakaryocytes expressing IFITM3 (magenta) are protected against dengue virus infection (yellow). Nuclei were stained with TO-PRO-3 (blue). See the article by Campbell et al on page 2013.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkEditorial Board
Advertisement intended for health care professionals
Email alerts
Advertisement intended for health care professionals